Brickell Biotech Inc (NASDAQ:BBI) Stock Takes a Hit After New Stock Offerings
Clinical stage pharmaceutical firm Brickell Biotech Inc (NASDAQ:BBI) saw its stock tank by as much as 25% on Thursday after it made an announcement with regards to its underwritten public offering. The company announced the pricing of the previously announced offering yesterday and it seems that the details did not quite thrill investors. Market Action: On Thursday, BBI stock lost 25.53% at $0.3990 with more than 19.49 million shares, compared…